ORMP shareholders re-elect board, approve incentive plan increase and triennial say-on-pay

ORAMED PHARMACEUTICALS INC.

All six directors re-elected; favorable votes ranged from 11.57M (Shapiro) to 13.70M (N. Kidron).
Ratification of Kesselman & Kesselman (PwC member) as 2026 fiscal year auditor passed: 22.24M for, 2.72M against.
2019 Stock Incentive Plan amendment approved, increasing authorized shares by 3M to 12.5M total.
Say-on-pay approved (13.01M for, 4.39M against); stockholders selected every-three-years frequency (11.38M for).
Board adopted triennial say-on-pay votes until the next required frequency vote.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.